The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors
Open accessAbstract
Despite the promising efficacy of immunoregulation in cancer therapy, the clinical benefit has been restricted by inefficient infiltration of lymphocytes in the evolution of immune evasion. Also, immune-related adverse events have often occurred due to the off-target binding of therapeutics to normal tissues after systematic treatment. In light of this, we have developed a synergistic immunotherapy strategy that locally targets the immunoinhibitory receptor programmed cell death protein 1 (PD1) and immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) for the treatment of melanoma through a microneedle-based transcutaneous delivery approach. The embedded immunotherapeutic nanocapsule loaded with anti-PD1 antibody (aPD1) is assembled from hyaluronic acid modified with 1-methyl-dl-tryptophan (1-MT), an inhibitor of IDO. This formulation method based on the combination strategy of "drug A in carriers formed by incorporation of drug B" facilitates the loading capacity of therapeutics. Moreover, the resulting delivery device elicits the sustained release and enhances retention of checkpoint inhibitors in the tumor microenvironment. Using a B16F10 mouse melanoma model, we demonstrate that this synergistic treatment has achieved potent antitumor efficacy, which is accompanied by enhanced effective T cell immunity as well as reduced immunosuppression in the local site.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-assembly of block copolymers
Mai, Y., & Eisenberg, A. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35115c · Cited by 3,610
Prausnitz, M. R., & Langer, R. (2008) · Nature Biotechnology · doi:10.1038/nbt.1504 · Cited by 3,517
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Microneedles for drug and vaccine delivery
Kim, Y.-C., Park, J.-H., & Prausnitz, M. R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.04.005 · Cited by 1,760
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Dissolving polymer microneedle patches for influenza vaccination
Sullivan, S. P., Koutsonanos, D. G., del Pilar Martin, M., Lee, J. W., Zarnitsyn, V., Choi, S.-O., Murthy, N., Compans, R. W., Skountzou, I., & Prausnitz, M. R. (2010) · Nature Medicine · doi:10.1038/nm.2182 · Cited by 948
Yu, J., Zhang, Y., Ye, Y., DiSanto, R., Sun, W., Ranson, D., Ligler, F. S., Buse, J. B., & Gu, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505405112 · Cited by 848
Self-citationEnhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H., & Gu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b05030 · Cited by 784
Self-citationTransformable liquid-metal nanomedicine
Lu, Y., Hu, Q., Lin, Y., Pacardo, D. B., Wang, C., Sun, W., Ligler, F. S., Dickey, M. D., & Gu, Z. (2015) · Nature Communications · doi:10.1038/ncomms10066 · Cited by 593
Self-citationReversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolušić, E., Frédérick, R., De Plaen, E., Uyttenhove, C., Wouters, J., Masereel, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113873109 · Cited by 572
Stimuli-responsive nanomaterials for therapeutic protein delivery
Lu, Y., Sun, W., & Gu, Z. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.08.015 · Cited by 415
Self-citationEngineering Nano‐ and Microparticles to Tune Immunity
Moon, J. J., Huang, B., & Irvine, D. J. (2012) · Advanced Materials · doi:10.1002/adma.201200446 · Cited by 404
Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody
Wang, C., Sun, W., Wright, G., Wang, A. Z., & Gu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201506312 · Cited by 344
Self-citationAccelerating the Translation of Nanomaterials in Biomedicine
Mitragotri, S., Anderson, D. G., Chen, X., Chow, E. K., Ho, D., Kabanov, A. V., Karp, J. M., Kataoka, K., Mirkin, C. A., Petrosko, S. H., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b03569 · Cited by 338
Self-citationTargeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0094-9 · Cited by 336
DeMuth, P. C., Moon, J. J., Suh, H., Hammond, P. T., & Irvine, D. J. (2012) · ACS Nano · doi:10.1021/nn302639r · Cited by 195
Hervé, C., Beyne, P., Jamault, H., & Delacoux, E. (1996) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/0378-4347(95)00341-x · Cited by 185
DeMuth, P. C., Min, Y., Irvine, D. J., & Hammond, P. T. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300139 · Cited by 171
Awuah, S. G., Zheng, Y.-R., Bruno, P. M., Hemann, M. T., & Lippard, S. J. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b10182 · Cited by 164
Hu, Q., Sun, W., Lu, Y., Bomba, H. N., Ye, Y., Jiang, T., Isaacson, A. J., & Gu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b04343 · Cited by 162
Self-citationBio-Inspired Synthetic Nanovesicles for Glucose-Responsive Release of Insulin
Tai, W., Mo, R., Di, J., Subramanian, V., Gu, X., Buse, J. B., & Gu, Z. (2014) · Biomacromolecules · doi:10.1021/bm500364a · Cited by 158
Self-citationBiomaterials for enhancing anti-cancer immunity
Koshy, S. T., & Mooney, D. J. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.02.001 · Cited by 135
Engineering opportunities in cancer immunotherapy
Jeanbart, L., & Swartz, M. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508516112 · Cited by 134
Engineered materials for cancer immunotherapy
Cheung, A. S., & Mooney, D. J. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.007 · Cited by 108
HWANG, S. L., Chung, N. P. Y., Chan, J. K., & Lin, C.-L. S. (2005) · Cell Research · doi:10.1038/sj.cr.7290282 · Cited by 107
Vaccine delivery with microneedle skin patches in nonhuman primates
DeMuth, P. C., Li, A., Abbink, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2759 · Cited by 105
Immune-checkpoint blockade — durable cancer control
Buchbinder, E. I., & Hodi, F. S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.237 · Cited by 87
Materials based tumor immunotherapy vaccines
Li, A. W., & Mooney, D. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.008 · Cited by 57
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Makvandi, P., Kirkby, M., Hutton, A. R. J., Shabani, M., Yiu, C. K. Y., Baghbantaraghdari, Z., Jamaledin, R., Carlotti, M., Mazzolai, B., Mattoli, V., et al. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00611-9 · Cited by 455
Feng, B., Zhou, F., Hou, B., Wang, D., Wang, T., Fu, Y., Ma, Y., Yu, H., & Li, Y. (2018) · Advanced Materials · doi:10.1002/adma.201803001 · Cited by 451
Engineering Magnetosomes for Ferroptosis/Immunomodulation Synergism in Cancer
Zhang, F., Li, F., Lu, G.-H., Nie, W., Zhang, L., Lv, Y., Bao, W., Gao, X., Wei, W., Pu, K., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b00892 · Cited by 357
Cheng, K., Ding, Y., Zhao, Y., Ye, S., Zhao, X., Zhang, Y., Ji, T., Wu, H., Wang, B., Anderson, G. J., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01071 · Cited by 325
Metadata
- Authors
- Ye, Y., Wang, J., Hu, Q., Hochu, G. M., Xin, H., Wang, C., & Gu, Z.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-09-06
- Volume
- 10
- Issue
- 9
- Pages
- 8956-8963
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2513541135
- Cited by
- 339
- References
- 41
- FWCI
- 15.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
